

CardioComm Solutions, Inc. and GE Healthcare Sign Long Term Software Agreement

Victoria, B.C., November 18, 2008 – CardioComm Solutions, Inc. (TSX-V: EKG) (“CardioComm” or the “Company”) is pleased to announce that it has executed a renewable four year North American software licensing agreement with General Electric Company through its GE Healthcare business focusing on cardiac arrhythmia management.

CardioComm’s patented Global ECG Management System (GEMST[™]) has been selected to be seamlessly integrated within GE’s arrhythmia analysis and diagnostic system and will provide a server based solution for both large cardiology practices and in hospital use.

“This collaboration sends a clear signal that CardioComm’s technology remains a preferred industry standard in the field of cardiac arrhythmia management,” says Etienne Grima, Chief Financial Officer for CardioComm Solutions, Inc.

About CardioComm Solutions, Inc.

CardioComm’s patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (EKGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time EKG viewer. CardioComm is the first company to provide a real-time means of viewing EKGs over a network (LAN, WAN or Internet). This tool enables EKGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global EKG Management System (GEMST[™]) and GlobalCardio[™]. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions, Inc.

“Anatoly Langer”

Dr. Anatoly Langer, Chairman

For investor information, please contact:

Ian Klassen
1-604-899-0106

*The TSX Venture Exchange has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release*